Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) [Phase 1]
The Phase 1 study of WU-NK-101 in relapsed or refractory acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) [Phase 2]
Phase 2 trial ACHIEVE evaluating adoptive cellular therapy with ex-vivo expanded allogeneic γδ T-lymphocytes (TCB008) for refractory or rela…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Retun-to-school Adaptation Program for Children With Cancer [NA]
Clinical trial update indicating the completion of a return-to-school adaptation program study for children with cancer, sponsored by Gazi U…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies [Phase 3]
A Phase 3 randomized trial evaluating Orca-T in allogeneic stem cell transplantation for hematologic malignancies; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) [Phase 1]
This clinical trial update reports the bioequivalence assessment of azacitidine 300 mg film-coated tablets in adults with acute myeloid leuk…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes [Phase 1]
This Phase 1 trial update reports results for CC-95251 in acute myeloid leukemia and myelodysplastic syndromes. The study has been terminate…
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
The CREST study update shows the cardiovascular reserve evaluation trial in transplant survivors is currently active but not recruiting, spo…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients [NA]
A completed single-arm clinical trial evaluating the combination of azacitidine and venetoclax in newly diagnosed, fit patients with acute m…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]
Phase 1 study of SGR-2921 in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-09-16Clinical Trial Update: Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
A Phase 1 clinical trial evaluating the combination of enasidenib with cobimetinib for relapsed or refractory acute myeloid leukemia; the st…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy [Phase 3]
This Phase 3 trial evaluated gilteritinib alone or with azacitidine versus azacitidine alone in adults with newly diagnosed acute myeloid le…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Post-transplant Flotetuzumab for AML [Phase 1]
Phase 1 results update for flotetuzumab in post-transplant acute myeloid leukemia. Results were posted on 2025-09-12.
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant
This clinical trial update discusses using gilteritinib to help maintain remission in patients with acute myeloid leukemia after stem cell t…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 study evaluating off-the-shelf natural killer cells SAR445419 for relapsed/refractory acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-09-11Clinical Trial Update: Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia [Phase 1]
Phase 1 trial of pitavastatin in combination with venetoclax for chronic lymphocytic leukemia or acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML [Phase 2, Phase 3]
This clinical trial evaluates radioimmunotherapy conditioning with 131I-apamistamab before allogeneic stem cell transplantation in patients …
-
CLINICAL_TRIALS trial_result · 2025-09-08Clinical Trial Update: PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK) [Phase 2]
Phase 2 trial of PF-05212384 (PKI-587) for therapy-related AML/MDS and de novo/relapsed or refractory AML was terminated. The update indicat…
-
CLINICAL_TRIALS trial_result · 2025-09-04Clinical Trial Update: Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1
Completion notice for NCT07155382 describing allogeneic hematopoietic cell transplantation using BuFluATG conditioning (busulfan, fludarabin…
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial) [Phase 2]
The Phase 2 CLARA (ALFA 0702) trial for Acute Myeloid Leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-27Clinical Trial Update: Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes [Phase 1]
Phase 1 study evaluating safety and tolerability of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia…
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia [Phase 2]
This Phase 2 trial examines hematopoietic stem cell transplantation for infant leukemia and has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)
This clinical trial update reports on the association between ex vivo drug response and clinical outcomes in acute myeloid leukemia, includi…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: MRD-guided Treatment in NPM1mut AML Patients [Phase 2]
A Phase 2 trial evaluating MRD-guided treatment in patients with NPM1-mutated acute myeloid leukemia has been terminated, per the clinical t…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML [Phase 1, Phase 2]
A Phase 1/2 trial of Luveltamab Tazevibulin (STRO-002) for relapsed/refractory CBFA2T3::GLIS2 AML in infants and children under 12 has been …
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies [Phase 1, Phase 2]
A study evaluating SAR443579, a natural killer cell engager, in combination with different agents for acute myeloid leukemia has been termin…